Clinical response to antidepressant treatment and 3-methoxy-4- hydroxyphenylglycol levels: Mini review

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 28, Issue 4, 2004, Pages 611-616

  Yoshimura, Reiji ^a   Nakamura, Jun ^a   Shinkai, Koji ^a   Ueda, Nobuhisa ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

3 Methoxy 4 hydroxyphenylglycol; 3 methoxy 4 hydroxyphenylglycol; Depression; Drug response; HPA; hypothalamic pituitary adrenal; MHPG

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; HYDROCORTISONE; IMIPRAMINE; MAPROTILINE; MILNACIPRAN; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NEUROTRANSMITTER; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; BLOOD LEVEL; CEREBROSPINAL FLUID; CLINICAL FEATURE; DEPRESSION; DRUG RESPONSE; HUMAN; MAJOR DEPRESSION; NORADRENERGIC NERVE; NORADRENERGIC SYSTEM; PERCEPTION; PSYCHOMOTOR RETARDATION; REVIEW; SEROTONINERGIC NERVE CELL;

ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER; HUMANS; METHOXYHYDROXYPHENYLGLYCOL;

EID: 3343021929     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2004.01.008     Document Type: Review

References (65)

1. Ballenger J.C. Psychopharmacology of the anxiety disorders. Psychiatr. Clin. North Am. 7:1984;757-771
2. Beckmann H., Goodwin F.K. Antidepressant response to tricyclics and urinary MHPG in unipolar patients. Clinical response to imipramine or amitriptyline. Arch. Gen. Psychiatry. 32:1975;17-21
3. Beckmann H., Murphy D.L. Phenelzine in depressed patients. Effects on urinary MHPG excretion in relation to clinical response. Neuropsychobiology. 3:1977;49-55
4. Charney D.S., Redmond D.E. Jr. Neurobiological mechanisms in human anxiety. Evidence supporting central noradrenergic hyperactivity. Neuropharmacology. 22:1983;1531-1536
5. Charney D.S., Heninger G.R., Sternberg D.E., Roth R.H. Plasma MHPG in depression: effects of acute and chronic desipramine treatment. Psychiatry Res. 5:1981;217-229
6. DeBellis M.D., Geracioti T.D. Jr., Altemus M., Kling M.A. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biol. Psychiatry. 33:1993;636-641
7. Drebing C.J., Freedman R., Waldo M., Gerhardt G.A. Unconjugated methoxylated catecholamine metabolites in human saliva. Quantitation methodology and comparison with plasma levels. Biomed. Chromatgr. 3:1989;217-220
8. Fawcett J., Maas J.W. Depression and MHPG excretion. Response to dextroamphetamine and tricyclic antidepressants. Arch. Gen. Psychiatry. 26:1972;246-251
9. Garvey M.J., Tollefson G.D., Orsulak P.T. Elevations of urinary MHPG in depressed patients with panic attacks. Psychiatry Res. 20:1987;183-187
10. Garvey M.J., Hollon S.D., DeRubeis R.J. Changes in urinary MHPG during treatment of depression with imipramine. Biol. Psychiatry. 34:1993;562-564
11. Goodnick P.J., Dominguez R.A., DeVane C.L., Bowden C.L. Bupropion slow-release response in depression: diagnosis and biochemistry. Biol. Psychiatry. 44:1998;629-632
12. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 32:1959;50-55
13. Hamilton M. The Hamilton rating scale for depression. Sartorius N., Ban T.A. Assessment of Depression. 1986;143-152 Springer, Berlin
14. Hollister L.E., David K.L., Berger P.A. Subtypes of depression based on MHPG and response to nortriptyline. Arch. Gen. Psychiatry. 37:1980;1107-1110
15. Jimerson D.C., Insel T.R., Reus V.I., Kopin I.J. Increased plasma MHPG in dexamethasone-resistant depressed patients. Arch. Gen. Psychiatry. 40:1983;173-176
16. Karege F., Bovier P.H., Gaillard J.M., Tissot R. Plasma MHPG and AMDP depression relations, evolution and drug effect in a follow up study of depressed patients. Hum. Psychopharmacol. 6:1991;11-17
17. Karege F., Bovier P., Hilleret H., Gaillard J.M. Lack of effect of anxiety on total plasma MHPG in depressed patients. J. Affect. Disord. 28:1993;211-217
18. Ko G.N., Elsworth J.D., Roth R.H., Rifkin B.G., Leigh H., Redmond D.E. Jr. Panic-induced elevation of plasma MHPG levels in phobic-anxious patients. Effects of clonidine and imipramine. Arch. Gen. Psychiatry. 40:1983;425-430
19. Ko H.C., Lu R.B., Shiah I.S., Hwang C.C. Plasma free 3-methoxy-4- hydroxyphenylglycol predicts response to fluoxetine. Biol. Psychiatry. 41:1997;774-781
20. Kopin I.J. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol. Rev. 37:1985;333-364
21. Koslow S.H., Maas J.W., Bowden C.L. CSF and urinary biogenic amines and metabolites in depression and mania. Arch. Gen. Psychiatry. 40:1983;999-1010
22. Lundmark J., Walinder J., Alling C., Manniche P.M., Dalgaard L. The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients. Eur. Neuropsychopharmacol. 4:1994;1-6
23. Maas J.M. Clinical and biochemical heterogeneity of depressive disorders. Ann. Intern. Med. 88:1978;556-563
24. Maas J.W., Hattox S.E., Greene N.M., Landis D.H. 3-Methoxy-4- hydroxyphenylethyleneglycol production by human brain in vivo. Science. 205:1979;1025-1027
25. Maas J.W., Kocsis J.H., Bowden C.L., Davis J.M., Redmond D.E., Hanin I., Robins E. Pretreatment neurotransmitter metabolites and response to imipramine or amitriptyline treatment. Psychol. Med. 12:1982;37-43
26. Maas J.W., Koslow S.H., Katz M.M. Pretreatment neurotransmitter levels and response to tricyclic antidepressant drugs. Am. J. Psychiatry. 141:1984;1159-1171
27. Markianos M., Alevizos B., Hatzimanolis J., Stefanis C. Effects of monoamine oxidase A inhibition on plasma biogemic amine metabolites in depressed patients. Psychiatry Res. 52:1994;259-264
28. Mason S.T., Fibiger H.C. Current concepts I Anxiety: the locus coeruleus disconnection. Life Sci. 25:1979;2141-2147
29. Mine K., Okada M., Mishima N., Fujiwara M., Nakagawa T. Plasma-free and sulfoconjugated MHPG in major depressive disorders: differences between responders to treatment and nonresponders. Biol. Psychiatry. 34:1993;654-660
30. Mooney J.J., Schatzberg A.F., Cole O. Rapid antidepressant response to alprazolam in depressed patients with high catecholamine output and heterologous desensitization of platelet adenylate cyclase. Biol. Psychiatry. 23:1988;543-559
31. Moooney J.J., Schatzberg A.F., Cole J.O., Samson J.A., Waternaux C., Gerson B., Pappalardo K.M., Schildkraut J.J. Urinary 3-methoxy-4- hydroxyphenylglycol and the depression-type score as predictors of differential responses to antidepressants. J. Clin. Psychopharmacol. 11:1991;339-343
32. Munjack D.J., Baltazar P.L., DeQuattro V., Sobin P., Palmer R., Zulueta A., Crocker B., Usigli R., Buckwalter G., Leonard M. generalized anxiety disorder: some biochemical aspects. Psychiatry Res. 32:1990;35-43
33. Nagaoka S., Iwamoto N., Arai H. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical response to haloperidol treatment. Biol. Psychiatry. 41:1997;857-864
34. Nakamura J., Yoshimura R. Effects of mianserin hydrochloride on delirium, especially postoperative delirium. Okuma T., Kanba S., Inoue Y. Recent Advances in the Research of Affective Disorder in Japan. 2002;173-184 Elsevier, Amsterdam
35. Nakamura J., Yoshimura R., Okuno T., Ueda N., Hachida M., Yasumoto K., Egami H., Maeda H., Nishi M., Aoyagi S. Association of plasma free-3-methoxy-4-hydroxyphenyl(ethylene)glycol, natural killer cell activity, and delirium in post-operative patients. Int. Clin. Psychopharmacol. 16:2001;339-343
36. Redmond D.E. Jr., Huang Y.H. Current concepts II New evidence for a locus coeruleus-norepinephrine connection with anxiety. Life Sci. 25:1979;2149-2162
37. Redmond D.E. Jr., Katz M.M., Maas J.W., Swann A., Casper R., Davis J.M. Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic and healthy control subjects. Arch. Gen. Psychiatry. 10:1986;938-947
38. Rosenbaum A.H., Schatzberg A.F., Jost F.A. III, Cross P.D., Wells L.A., Jiang N.S., Maruta T. Urinary free cortisol levels in anxiety. Psychosomatics. 24:1983;835-837
39. Rosenbaum A.H., Maruta T., Schatzberg A.F., Orsulak P.J., Jiang N.S., Cole J.O., Schildkraut J.J. Toward a biochemical classification of depressive disorders: VII. Urinary free cortisol and urinary MHPG in depressions. Am. J. Psychiatry. 140:1983;314-318
40. Roy A., Jimmerson D.C., Pickar D. Plasma MHPG in depressive disorders and relationship to the dexamethasone suppression test. Am. J. Psychiatry. 143:1986;846-851
41. Rubin A.L., Price L.H., Charney D.S., Heninger G.R. Noradrenergic function and the cortisol response to dexamethasone in depression. Psychiatry Res. 15:1985;5-15
42. Samson J.A., Mirin S.M., Hauser S.T., Fenton B.T., Schildkraut J.J. Learned helplessness and urinary MHPG levels in unipolar depression. Am. J. Psychiatry. 149:1992;806-809
43. Samson J.A., Mirin S.M., Griffin M., Borrelli D., Schildkraut J.J. Urinary MHPG and clinical symptoms in patients with unipolar depression. Psychiatry Res. 51:1994;157-165
44. Schatzberg A.F., Schildkraut A.F. Recent studies on norepinephrine systems in mood disorders. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;911-920 Raven Press, New York, NY
45. Schatzberg A.F., Rosenbaum A.H., Orsulak P. Toward a biochemical classification of depressive disorders: III. Pretreatment urinary MHPG levels as predictors of response to treatment with maprotiline. Psychopharmacology. 75:1981;34-38
46. Schatzberg A.F., Orsulak P.J., Rosenbaum A.H. Toward a biochemical classification of depressive disorders: V. Heterogeneity of unipolar depressions. Am. J. Psychiatry. 139:1982;471-475
47. Schatzberg A.F., Bowden C.L., Rosenbaum A.H., Schildkraut J.J. Prediction of response to fluoxetine versus desipramine. CME Syllabus and Proceedings Summary, 145th Annual Meeting. 1992;44 American Psychiatric Association, Washington, DC
48. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry. 122:1965;509-522
49. Serretti A., Lilli R., Smeraldi E. Pharmacogenetics in affective disorders. Eur. J. Pharmacol. 438:2002;117-128
50. Sharma, R.P., Janicak, P.G., Javaid, J.I., Pandey, G.N., Gierl, B., Davis, J.M., 1990. Platelet MAO inhibition, urinary MHPG, and leukocyte beta-adrenergic receptors in depressed patients treated with phenelzine.
51. Sheline Y., Bardgett M.E., Csernansky J.G. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors. J. Clin. Psychopharmacol. 17:1997;11-14
52. Shinkai K., Yoshimura R., Ueda N., Okamoto K., Nakamura J. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to mainaciplan versus paroxetine. J. Clin. Psychopharmacol. 24:2004;11-17
53. Slaap B.R., Van Vilet I.M., Westenberg H.G., Den Boer J.A. MHPG and heart rate as correlates of nonresponse to drug therapy in panic disorder patients. A preliminary report. Psychopharmacology. 127:1996;353-358
54. Siever L.J., Davis K.L. Overview: toward a dysregulation hypothesis of depression. Am. J. Psychiatry. 142:1985;1017-1031
55. Siever L.J., Uhde T.W. New studies and perspectives on the noradrenergic receptors system in depression: effects of the alpha 2-adrenergic agonist clonidine. Biol. Psychiatry. 19:1984;131-156
56. Southwick S.M., Krystal J.H., Morgan C.A., Johnson D., Nagy L.M., Nicolaou A., Heninger G.R., Charney D.S. Abnormal noradrenergic function in posttraumatic stress disorder. Arch. Gen. Psychiatry. 50:1993;266-274
57. Stahl S.M. Essential Psychopharmacology. 2000;Cambridge Univ. Press, Cambridge, UK
58. Stefanis C.N., Alevizos B., Markianos M., Hatzimanolis J. Effect of moclobemide on clinical and neurochemical variables in depressed patients (preliminary findings). J. Neural Transm. 26(Suppl.):1988;87-95
59. Szabo S.T., Blier P. Effect of combined 5-HT reuptake inhibition and 5-HT2A antagonism on the firing activity of NE neurons. Abstr.-Soc. Neurosci. 26:2000;s1928
60. Ueda N., Yoshimura R., Nakamura J. Fluvoxamine improves some depressive symptoms by influencing noradrenergic neurons. Psychiatry Res. 2004;. (in press)
61. Yamada S., Yajima J., Harano K., Miki K., Nakamura J., Tsuda A., Shoji H., Maeda H., Tanaka M. Saliva level of free 3-methoxy-4-hydroxyphenylglycol in psychiatric outpatients with anxiety. Int. Clin. Psychopharmacol. 13:1998;213-217
62. Yamada S., Yamauchi K., Yajima J., Hisadomi S., Maeda H., Toyomatsu K., Tanaka M. Saliva level of free 3-methoxy-4-hydroxyphenylglycol (MHPG) as a biological index of anxiety disorders. Psychiatry Res. 93:2000;217-223
63. Yazici O., Aricioglu F., Gurvit G., Ucok A., Tastaban Y., Canberk O., Ozguroglu M., Durat T., Sahin D. Noradrenergic and serotonergic depression? J. Affect. Disord. 27:1993;123-129
64. Yoshimura R., Nakamura J., Ueda N., Terao T. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement. Int. Clin. Psychopharmacol. 15:2000;175-180
65. Yoshimura R., Yamada Y., Ueda U., Nakamura J. Changes in plasma monoamine metabolites during acute lithium intoxication. Hum. Psychopharmacol. 15:2000;357-360